Radical vs Local Excision for Rectal Cancer With Clinically Complete Remission
Rectal Cancer
About this trial
This is an interventional treatment trial for Rectal Cancer focused on measuring Rectal cancer, Concomitant chemoradiation therapy, Radical surgery, Local excision
Eligibility Criteria
Inclusion Criteria: rectal adenocarcinoma completed nCRT and the imaging studies showed no residual malignancy; physical status is within American Society of Anesthesiology(ASA)class Ⅰ to Ⅲ; the lesion side can be reached by the transanal local excision, generally within 6 cm above anal verge; age is 18-75 years. Exclusion Criteria: Quantification of ct DNA shows residual malignancy; Body mass index(BMI)>40 kg/m2; Previous abdominal or pelvic surgery; abnormal hepatologic (Bil>2.0 mg/dl), renal (Cre≧2.0) and hematologic(WBC<3000, HB<8.0, platelet<50000) profiles after CCRT.
Sites / Locations
- Jin-Tung LIANGRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Watch and wait group
Surgical group
In this group, the patients with clinically complete response will undergo non-surgical treatment (watch-and-wait group)
In this group, the patients with clinically complete response will undergo surgical treatment (LAR with anal preservation or APR)